Navigation Links
Access Pharmaceuticals Presents New Data on the Company's Angiolix(R) Therapeutic Monoclonal Antibody
Date:10/2/2008

Data Indicate Dual Modes of Action and Synergy with Chemotherapy

DALLAS, Oct. 2 /PRNewswire-FirstCall/ -- Access Pharmaceuticals, Inc. (OTC Bulletin Board: ACCP) presented data this week from preclinical studies on Angiolix showing that by blocking lactadherin, Angiolix has both an anti-angiogenic effect as well as a direct anti-proliferative effect on tumors themselves. In preclinical models of human breast cancer (MX-1), Angiolix had a significant anti-cancer effect in vivo; this effect was enhanced when Angiolix was given in combination with conventional chemotherapy for breast cancer. The studies were conducted at Imperial College London and presented at the International Conference titled "Realizing the Commercial Potential of Therapeutic Antibodies," held in London, UK.

"We are delighted with these results which demonstrate the substantial anti-cancer effect of Angiolix, which we feel is comparable to Avastin yet achieved through a different and potentially complementary mechanism of action," stated Jeffrey B. Davis, President & CEO. "As stated previously, Access is actively seeking potential partners for the further clinical development of Angiolix."

"Angiolix is highly tumor specific," continued Agamemnon Epenetos, Chief Scientific Officer, Europe, "because the target lactadherin is primarily found in tumors and not in normal tissues. Other targets, such as VEGF, are present in many normal tissues; the blocking of VEGF may contribute to side effects such as high blood pressure and bleeding episodes, for example. Angiolix appears to be a more tumor selective anti-angiogenesis monoclonal antibody, with the benefit of having anti-proliferative activity."

Access is continuing to conduct pre-clinical studies at Imperial College London to more fully define the safety and efficacy profile of Angiolix.

About Angiolix:

Angiolix is a novel humanized monoclonal antibody which has considerable potential for the treatmen
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
2. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
3. Hypertension: Journal of the American Heart Association Rapid Access Reports: Hispanics Hypertension Better Controlled With Equal Access to Care
4. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
5. Access Pharmaceuticals to Present Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
6. Access Pharmaceuticals Announces Two Poster Presentations Reporting Significant Preclinical Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
7. Demand for Spanish-Language Cancer Web Materials Quadruples; Internet Resources and Access Remain Scarce
8. New Analysis from 14 Countries Identifies Drug Access Priorities to Achieve 2010 AIDS Treatment Target
9. Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin
10. Childrens Hospital Cancer Study Finds Adolescents and Young Adults Dont Get Same Access to Cutting-Edge Treatment as Younger Patients
11. Insmed Provides Update on IPLEX(TM) Expanded Access Program in Italy for the Treatment of Amyotrophic Lateral Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... N.C. , Dec. 23, 2014  Endo Pharmaceuticals ... ENDP ) (TSX: ENL), and BioDelivery Sciences International, ... they have submitted a New Drug Application (NDA) for ... Drug Administration (FDA).  Buprenorphine HCl Buccal Film is under ... require daily, around-the-clock, long-term opioid treatment and for which ...
(Date:12/22/2014)... and Markets ( http://www.researchandmarkets.com/research/h3xm6q/us ) has announced ... Market" report to their offering. ... focuses on the developments in the self-monitoring blood glucose ... Reimbursement analysis and the effects of competitive bidding have ... SMBG meters have been performed, based on the various ...
(Date:12/22/2014)... and STOCKHOLM , Dec. 22, ... and partner Auxilium Pharmaceuticals, Inc. today announced that the ... the European Medicines Agency (EMA) has adopted a positive ... for the treatment of adult men with Peyronie,s disease ... least 30 degrees at the start of therapy. ...
Breaking Medicine Technology:Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 5US Self-monitoring Blood Glucose Market 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6
... PLC Systems Inc. (OTCBB: PLCSF), a company focused ... has named Susan Papalia, RN, BSN, Vice President of ... responsible for overseeing and leading the U.S. clinical study ... obtained the CE Mark in the European Union, and ...
... Pharmaceuticals Inc. today announced that Prabhavathi Fernandes, Ph.D., president and ... in Paris.  Dr. Fernandes will present at the 18th ... at the Hilton Arc de Triomphe.  Dr. Fernandes will later ... CET, May 24, at the Paris Marriott Rive Gauche.  Dr. ...
Cached Medicine Technology:PLC Medical Systems Adds Vice President of Clinical Affairs 2PLC Medical Systems Adds Vice President of Clinical Affairs 3Cempra Pharmaceuticals to Present at Two Investor Conferences in Paris 2
(Date:12/25/2014)... (PRWEB) December 25, 2014 Helen Harris’ ... in Woodland Hills, California after an 8 year battle ... on Christmas Eve evening in her home in Woodland ... metastatic breast cancer. , As the ... forty years, she pioneered and championed many of today's ...
(Date:12/25/2014)... LunaDress.co.uk has updated its blog to provide professional shopping tips on ... models at LunaDress.co.uk come with big discounts, up to 80 percent ... turn out to be a most exciting memory and can show ... surprise to a wedding. On the updated fashion blog, ladies can ... a big day . , Going out with friends to a ...
(Date:12/25/2014)... 25, 2014 (HealthDay News) -- The risk of burns ... so you need to be extra cautious, an expert ... see a significant increase in patients coming in with ... Suffolk County Volunteer Firefighters Burn Center of Stony Brook ... be full of joy, but if not careful, could ...
(Date:12/25/2014)... News) -- Among early stage breast cancer patients who ... one percent will eventually develop leukemia as a result ... finding comes from a review of more than 20,000 ... it suggests that the risk for developing treatment-related leukemia, ... thought. "The frequency of bone marrow cancers such ...
(Date:12/25/2014)... AngelWeddingDress.com tries its best to translate the experience ... business has introduced its new collection of 2015 prom ... The new prom outfits are guaranteed to contain the ... are specially designed for 2015. Anyone who wants to ... its website before Jan. 26, 2015, the deadline of ...
Breaking Medicine News(10 mins):Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Don't Let Burns Mar Your Holidays 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3Health News:Angelweddingdress 2015 Prom Dresses Online Now 2
... networks , , FRIDAY, April 24 (HealthDay News) -- Better ... has led to steady improvements in the time needed ... heart attack, new research shows. , The study involved ... myocardial infarction (STEMI), the deadliest type of heart attack. ...
... researchers report , , FRIDAY, April 24 (HealthDay News) -- ... after heart bypass surgery are at increased long-term risk ... sounds a warning bell for doctors about an issue ... said Giovanni Filardo, director of the department of epidemiology ...
... advantage, study finds, , , FRIDAY, April 24 (HealthDay News) -- ... in better health than the general population, but for veterans ... , In fact, aging combat veterans have a poorer quality ... that was to be presented Friday at the American Heart ...
... New policy papers addressing comprehensive payment reform and ... released today by the American College of Physicians ... , Reforming Physician Payments to Achieve Greater ... Challenges Facing Primary Care Medicine: Comprehensive Strategies from ...
... Talecris Biotherapeutics, Inc. today announced the publication ... the largest clinical trial ever conducted in patients ... April 14, 2009 issue of Neurology . ... Gamunex (Immune Globulin Intravenous (Human), 10% Caprylate/Chromatography Purified) ...
... Drug Companies to Adopt "Smart" Drug Safety TechnologyARMONK, N.Y. ... -- IBM (NYSE: IBM ... Golden State Medical Supply (GSMS) today announced the two ... with stringent prescription drug pedigree regulations in advance of ...
Cached Medicine News:Health News:Coordination Has Led to Quicker Heart Treatment 2Health News:Abnormal Heartbeat After Bypass a Bad Sign 2Health News:Combat Duty Harms Long-Term Health of Vets 2Health News:Combat Duty Harms Long-Term Health of Vets 3Health News:Payment reform and solutions to challenges facing primary care addressed in policy papers 2Health News:Payment reform and solutions to challenges facing primary care addressed in policy papers 3Health News:Landmark study demonstrates Gamunex improves health-related quality of life in patients with CIDP 2Health News:Landmark study demonstrates Gamunex improves health-related quality of life in patients with CIDP 3Health News:IBM and Golden State Medical Supply Create Drug Safety Model to Help Combat Counterfeiting 2Health News:IBM and Golden State Medical Supply Create Drug Safety Model to Help Combat Counterfeiting 3
Auto refractometer....
A system with integrated pupil camera and 7" examination monitor. An easy to use configuration....
... The Selecta II Glaucoma Laser System features ... patients with open-angle glaucoma. It selectively targets ... intraocular pressure. The Selecta II is equipped ... high-energy beam of light, which induces the ...
Round handle....
Medicine Products: